Quantum BioPharma Unaware of Any Material Change

Company Overview - Quantum BioPharma Ltd. is a biopharmaceutical company focused on developing innovative assets and biotech solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [2] - The company is advancing its lead compound, Lucid-MS, which is designed to prevent and reverse myelin degradation, a key factor in multiple sclerosis, demonstrated in preclinical models [2] - Quantum BioPharma owns 25.71% of Celly Nutrition Corp., which markets the product unbuzzd™, and has a royalty agreement that includes 7% of sales until total payments reach $250 million, after which the royalty rate drops to 3% [2] Recent Market Activity - The Canadian Investment Regulatory Organization has requested confirmation from Quantum BioPharma regarding recent market activity, to which the company stated that management is unaware of any material changes in operations that would explain this increase [1]